Please ensure Javascript is enabled for purposes of website accessibility

Why STAAR Surgical Stock Is Skyrocketing Today

By Keith Speights - Aug 1, 2019 at 3:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Great second-quarter earnings results sent the implantable contact lens maker's stock into orbit.

What happened

Shares of STAAR Surgical (STAA -3.26%) were skyrocketing 18.5% higher as of 3 p.m. EDT on Thursday. The big gain came after the maker of implantable contact lenses and companion delivery systems announced stellar second-quarter results on Wednesday after the market closed.

So what

STAAR reported record-high Q2 revenue of $39.7 million, up 17% year over year. Its revenue looked even better on a constant-currency basis with year-over-year growth of 19%. The company announced earnings per share (EPS) of $0.08, doubling its EPS from the prior-year period. 

Closeup of eye with computer-generated image in front of the eye

Image source: Getty Images.

The real reason behind STAAR Surgical's impressive gain today, though, stemmed from how much better the company performed versus expectations. STAAR narrowly topped analysts' consensus revenue estimate of $39.56 million but blew away Wall Street's earnings estimate of $0.05 per share.

Perhaps the best news of all was that the company's implantable contact lens (ICL) products continue to enjoy strong momentum in the marketplace. STAAR Surgical CEO Caren Mason said that ICL units grew in all geographic areas, with especially strong growth in China, Korea, and smaller Asia Pacific markets.

Now what

STAAR Surgical should have more good news on the way. Mason stated that the Q2 results "put us firmly on track to achieve or exceed our full-year targets for 30% ICL unit growth, 20% company revenue growth, achievement of year-over-year improvements in GAAP [generally accepted accounting principles] net income, positive cash flow generation, and a higher level of cash on our balance sheet."

The company also recently submitted data to European regulators from its multi-site clinical trial of its extended depth of focus (EDOF) lens for presbyopia (age-related farsightedness). STARR also filed a revised submission to the U.S. Food and Drug Administration for what the company referred to as "a least burdensome pathway forward encompassing a clinical trial for our EVO family of lenses in the U.S."

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

STAAR Surgical Company Stock Quote
STAAR Surgical Company
$72.70 (-3.26%) $-2.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.